{"id":"W2152957042","doi":"10.1093/eurheartj/eht135","title":"Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial","year":2013,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"Servier; Astellas Pharma; Regado Biosciences; Duke Clinical Research Institute; Daiichi-Sankyo; Medicines Company; Boston Scientific Corporation; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; F. Hoffmann-La Roche; GlaxoSmithKline; Amgen; Pfizer; Sanofi; Abbott Laboratories","keywords":"Medicine; Apixaban; Atrial fibrillation; Warfarin; Internal medicine; Cardiology; Duration (music); Rivaroxaban","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007150228,0.00009466122,0.0002947435,0.00004925769,0.00009825762,0.00004420873,0.00005883172,0.00003004526,0.0002292578],"category_scores_gemma":[0.001002171,0.00005845696,0.0001473614,0.0001212625,0.00005742193,0.0001318773,0.00004774753,0.0001253004,0.0000473584],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001246191,"about_ca_system_score_gemma":0.00003218919,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007502834,"about_ca_topic_score_gemma":0.000001568561,"domain_scores_codex":[0.9985865,0.0002527776,0.000658002,0.0001148325,0.0002907699,0.00009713],"domain_scores_gemma":[0.9988046,0.0004029838,0.000381759,0.0001810617,0.0001595326,0.00007012102],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01841387,0.000009920675,0.8714853,0.00001407342,0.0003222967,0.000004101966,0.0007444074,0.00005635112,0.003450215,0.00008562105,0.0974842,0.007929681],"study_design_scores_gemma":[0.0211073,0.0005291303,0.8811107,0.00003188289,0.0001170959,0.00001265443,0.00008944239,0.0001225401,0.0002062385,0.00008027806,0.09651924,0.00007353696],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98717,0.00038773,0.00004686317,0.009656364,0.0006553777,0.0004224532,0.00001360064,0.00001367094,0.001633972],"genre_scores_gemma":[0.9952609,0.0001543377,0.0005763894,0.0001253197,0.002496366,6.032379e-8,0.00003483807,0.00001530496,0.001336477],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009625396,"threshold_uncertainty_score":0.2510212,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08043531922564112,"score_gpt":0.3264934249058093,"score_spread":0.2460581056801682,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}